Recipharm named Vikas Gupta as President of its recently renamed biologics business arm. Gupta joins ReciBioPharm from Repligen, where he was Vice President & General Manager, Gene Therapy and Downstream Bioprocessing. The appointment comes as Recipharm officially renames its biologics business division after the acquisitions of Arranta Bio, GenIbet and Vibalogics.
1st Jan change | Capi. | |
---|---|---|
+3.40% | 69.85B | |
+11.77% | 8.98B | |
-12.75% | 4.89B | |
+42.38% | 4.44B | |
+5.23% | 3.95B | |
+23.04% | 2.49B | |
-19.05% | 2.4B | |
-28.72% | 2.28B | |
+11.13% | 1.96B |